Results 1 to 10 of about 70,065 (194)
Sirolimus-induced acneiform eruption.
, 2005 Sirolimus is a new immunosuppressive agent used to prevent rejection in renal allograft recipients in order to reduce the need of potentially nephrotoxic calcineurin inhibitors (cyclosporine, tacrolimus).
Kunzle, N. +4 more
core +1 more source
Sirolimus-induced regression of a large orbital lymphangioma.
, 2018 Microcystic lymphatic malformations are difficult to treat surgically, especially when located in the orbital apex. Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic ...
Rössler, Jochen Karl +11 more
core +1 more source
, 2012 *Values are means (standard deviation).†Continuation was defined as the proportion of patients who remained on the sirolimus treatment.‡Adherence was defined for each specific time interval as the average daily proportion of patients who took their ...
James Young (44149) +14 more
core +1 more source
Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
, 2021 OBJECTIVES Clinical studies have shown low toxicity and a favorable safety profile for sirolimus in vascular anomalies. Here, we describe severe adverse events (SAEs) observed during "off-label use" for vascular anomalies. METHODS We performed a
Davila, Victoria +34 more
core +1 more source
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. [PDF]
, 2009 BACKGROUND: There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI)
Brodie, Bruce R. +23 more
core +1 more source
, 2008 The objective of this prospective randomized study was to verify whether the superiority of the sirolimus-eluting stent (SES) in inhibiting neointimal hyperplasia could be demonstrated in complex coronary lesions. The SES was compared with the paclitaxel-
BRANCHITTA, GIULIA
core
, 2008 Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI).
N. d. Cesare +17 more
core +1 more source
Sirolimus Induced Toxic Optic Neuropathy
, 2023 ObjectiveTo describe a case of optic neuropathy after prolonged sirolimus therapy in the setting of cardiac transplant. BackgroundSirolimus is an immunosuppressant that inhibits Mechanistic Target of Rapamycin (mTOR) and blocks T-cell activation and B ...
Lam, Byron L +2 more
core +1 more source
, 2013 Sirolimus has recently been introduced as a therapeutic agent for breast and prostate cancer. In the current study, conventional and Stealth® liposomes were used as carriers for the encapsulation of sirolimus.
Onyesome, Ichioma +11 more
core +1 more source
Effect of sirolimus on renal phosphate excretion.
, 2012 Trajectories of urinary phosphate/creatinine ratios of sirolimus and vehicle treated rats. Sirolimus caused statistically significant increased urinary phosphate excretion 24 hours after the first sirolimus injection (day 2) until after seven sirolimus ...
Maria Haller (146037) +10 more
core +1 more source